<DOC>
	<DOCNO>NCT02648100</DOCNO>
	<brief_summary>Muscle invasive ( MIBC ) and/or metastatic bladder cancer associate poor prognosis target therapy pathology currently validate . By 40 gene expression signature realize frozen sample , previously identify aggressive sub-class MIBC , call basal . This sub-class ( 20 % MIBC ) show strong EGFR dependence vitro vivo ( Rebouissou et al . Science Translational Medicine 2014 ) . This observation suggest possible response EGFR target therapy patient subgroup . Our aim establish standard diagnostic tool differentiate basal subtype bladder cancer evaluate effect anti-EGFR therapy , analyze previous clinical trial ( GETUG19 ) preclinical model , compare classical chemotherapy anti-EGFR associated chemotherapy .</brief_summary>
	<brief_title>Basal Like Bladder Cancer : Signature Therapeutic</brief_title>
	<detailed_description>The aim study : 1 . To validate diagnostic test formalin-fixed paraffin-embedded ( FFPE ) sample Nanostring technology , use 40 gene signature reference . First , compare frozen FFPE tissue ( n=120 ) , establish transcriptional signature FFPE sample . Secondly , characterize basal subtype bladder cancer , study mutational gain/loss landscape immunohistochemistry marker new series tumor classify gene signature ( n=510 ) . These characteristic include new signature define optimal prediction discrimination AIC et Net Reclassification Index . 2 . To assess prognosis cisplatine treatment 510 patient treated cystectomy without adjuvant chemotherapy ( pT2/pT3/pT4 , N0 N+ ) another multicentric series 188 patient treated cystectomy adjuvant chemotherapy ( pT3/pT4 et/ou N+ ) . Uni multi variant analysis realize adjust Cox model , add value basal subtype compare standard prognostic factor evaluate . The propensity score realize assess association basal subtype response chemotherapy . The anti-EGFR response analyze clinical trial GETUG19 use Panitumumab patient metastatic urothelial carcinoma ( n=93 ) 3 . To study treatment response preclinical model . We characterize previously preclinical murine model derive xenograft MIBC ( n=14 new xenograft add ) . We study effect anti-EGFR alone combination chemotherapy basal non basal subtypes xenograft . By study able good characterize basal subtype bladder cancer confirm aggressive behaviour compare subtypes MIBC . These result help establish new clinical trial include anti-EGFR patient basal subtype .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Muscle invasive bladder cancer Treatment cystectomy Adjuvant chemotherapy 3rd cohort Clinical trial GETUG 19 4th cohort FFPE material available Followup data available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Muscle invasive bladder cancer</keyword>
	<keyword>Basal subtype</keyword>
	<keyword>Anti-EGFR treatment</keyword>
	<keyword>Nanostring</keyword>
</DOC>